JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Toshifumi Murashita
Takashi Kunihara
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murashita, T.
Right arrow Articles by Sugiki, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murashita, T.
Right arrow Articles by Sugiki, H.
Related Collections
Right arrow Cardiac - other
Right arrow Mechanical Circulatory Assistance

J Thorac Cardiovasc Surg 2006;132:432-433
© 2006 The American Association for Thoracic Surgery

Brief Communication

A case of giant cell myocarditis: Bridge to recovery by long-term mechanical circulatory support without immunosuppressive therapy

Toshifumi Murashita, MD, PhD * , Takashi Sugiki, MD, Tsuyoshi Tachibana, MD, PhD, Takashi Kunihara, MD, PhD, Hiroshi Sugiki, MD

Department of Cardiovascular Surgery, Hokkaido University Hospital, Sapporo, Japan

Received for publication November 27, 2005; accepted for publication April 25, 2006.

* Address for reprints: Toshifumi Murashita, MD, PhD, Department of Cardiovascular Surgery, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo 060-8648, Japan (Email: muratosh@med.hokudai.ac.jp).

The first 20% of the full text of this article appears below.

Giant cell myocarditis (GCM) is an uncommon and rapidly fatal disorder resulting in cardiac transplantation or death. 1 Go Immunosuppressive therapy could prolong the average transplant-free survival period of patients GCM. The ventricular-assist device (VAD) usually provides support during the period of assessment of transplant candidacy, and there is only 1 reported case of a bridge to recovery with immunosuppression. 2 Go We report the unusual case of a young patient with cardiogenic shock caused by GCM who recovered after 7 months of left ventricular assistance without immunosuppressive therapy.

Clinical Summary

A 28-year-old woman (158 cm, 39 kg) had been experiencing progressive symptoms, including fatigue and dyspnea. An electrocardiogram showed complete heart block, and an echocardiogram showed a left ventricular ejection fraction (LVEF) of 0.17 with a dilated left ventricle. Despite support with intra-aortic balloon pumping and percutaneous cardiopulmonary support, the lack of improvement of left ventricular function led to the need for a left VAD. The left VAD (Toyobo VAD; Toyobo Ltd, Osaka, Japan) . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
L. K. Murray, J. Gonzalez-Costello, S. N. Jonas, D. B. Sims, K. A. Morrison, P. C. Colombo, D. M. Mancini, S. W. Restaino, E. Joye, E. Horn, et al.
Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis
Eur J Heart Fail, January 20, 2012; (2012) hfr174v1.
[Abstract] [Full Text] [PDF]

Home page
 Interact CardioVasc Thorac SurgHome page
W. C. Yeen, G. Haas, S. A. Mehmood, and J. A. Crestanello
Relapse of giant cell myocarditis supported with veno-arterial extracorporeal membrane oxygenation
Interact CardioVasc Thorac Surg, May 1, 2011; 12(5): 829 - 831.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.